Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PDE1A | P54750 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19159359 | 0.81 | HTR2A (0.45) | KMOHTR2AHTR2CHTR2BPDE1A | |
| SCHEMBL6740869 | 0.79 | KMO (0.38) | KMOHTR2AHTR2CHTR2BPDE1A | |
| SCHEMBL31638076 | 0.78 | CTNNB1 (0.51) | HTR2APDE1CCACNA1H | |
| SCHEMBL5792520 | 0.76 | KMO (0.40) | KMOHTR2AHTR2CHTR2BPLA2G4A | |
| SCHEMBL27165385 | 0.76 | HTR2A (0.51) | KMOHTR2AHTR2CHTR2BQPCT | |
| SCHEMBL27165379 | 0.75 | HTR2A (0.54) | KMOHTR2AHTR2CHTR2BMCHR1 | |
| SCHEMBL17504300 | 0.75 | KMO (0.55) | KMOHTR2AHTR2CHTR2BQPCT | |
| SCHEMBL6746000 | 0.74 | HRH3 (0.40) | KMOHTR2AHTR2CHTR2BPDE1A | |
| SCHEMBL6741339 | 0.73 | HRH3 (0.50) | MCHR1POLB | |
| SCHEMBL6744654 | 0.73 | QPCT (0.38) | KMOHTR2AHTR2CHTR2BQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | KMO 453/4885HTR2A 294/4885HTR2C 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.